Cargando…
How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician
Managing inflammatory bowel disease (IBD) during the coronavirus disease 2019 (COVID-19) pandemic has been a challenge faced by clinicians and their patients, especially concerning whether to proceed with biologics and immunosuppressive agents in the background of a global outbreak of a highly conta...
Autores principales: | Chebli, Júlio Maria Fonseca, Queiroz, Natália Sousa Freitas, Damião, Adérson Omar Mourão Cintra, Chebli, Liliana Andrade, Costa, Márcia Henriques de Magalhães, Parra, Rogério Serafim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985732/ https://www.ncbi.nlm.nih.gov/pubmed/33776370 http://dx.doi.org/10.3748/wjg.v27.i11.1022 |
Ejemplares similares
-
A guide to preparation of patients with inflammatory bowel diseases for anti-TNF-α therapy
por: Chebli, Júlio Maria Fonseca, et al.
Publicado: (2014) -
Risk stratification and geographical mapping of Brazilian inflammatory bowel disease patients during the COVID-19 outbreak: Results from a nationwide survey
por: Queiroz, Natália Sousa Freitas, et al.
Publicado: (2021) -
Efficacy of Early Optimization of Infliximab Guided by Therapeutic Drug Monitoring during Induction—A Prospective Trial
por: Garcia, Karoline Soares, et al.
Publicado: (2023) -
Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study
por: Parra, Rogério Serafim, et al.
Publicado: (2022) -
Leukocytoclastic Vasculitis Secondary to Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Diseases: A Multicenter Retrospective Cohort Study
por: Parra, Rogério Serafim, et al.
Publicado: (2023)